Literature DB >> 8190581

Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era.

C E Johnson1, D R Nalin, L W Chui, J Whitwell, R G Marusyk, M L Kumar.   

Abstract

HYPOTHESIS: The low titer of measles antibody in infants of mothers with vaccine-induced immunity may allow immunization against measles before 15 months of age.
METHODS: Six- and 15-month-old infants born to mothers < or = 30 years of age with no history of measles were recruited. Infants enrolled at 6 months of age were immunized with monovalent measles vaccine (Attenuvax), and maternal serum and infant pre- and postvaccination sera were obtained. Those enrolled for primary vaccination at 15 months of age received either Attenuvax (N = 12) or M-M-RII (N = 3). Six-month-old infants were revaccinated with M-M-RII at 15 months of age; pre- and postrevaccination sera were again obtained. Three antibody assays were used: a measles neutralizing assay (NT) and two enzyme immunoassays (EIA) for measles IgG and measles IgM.
RESULTS: Among primary vaccinees, 14 of 19 infants aged 6 months (74%) developed NT antibody, as did 15 of 15 infants aged 15 months (100%). The reciprocal geometric mean titer of 6-month-old seroresponders was 23.3, significantly lower than that of the 15-month-old primary vaccinees (87.7, P < .001). Primary seroconversion rates by EIA were 53% for 6-month-old infants and 100% for those aged 15 months. Revaccination of infants who had received Attenuvax at 6 months of age resulted in 100% NT positivity; the geometric mean titer rose to equal that of the group given primary immunization at 15 months of age. Measles IgM antibody was detected in 10 of 14 infants tested 1 month after primary vaccination at 15 months, but was not detected in any of the revaccinated infants after the second dose at 15 months of age (P < .001).
CONCLUSIONS: 1) Immunization with measles vaccine in infants born to vaccine-immune mothers at 6 months of age induced NT antibody in 74% of infants. 2) Revaccination of prior 6-month-old vaccinees at 15 months resulted in antibody titers equivalent to 15-month-old vaccinees. 3) Lack of an IgM response following revaccination suggests that even seronegative infants may be primed to respond on re-exposure to measles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8190581

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  9 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

2.  Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses.

Authors:  C Nicoara; K Zäch; D Trachsel; D Germann; L Matter
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

3.  Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.

Authors:  Hayley A Gans; Linda L Yasukawa; Phillip Sung; Barbara Sullivan; Ross DeHovitz; Susette Audet; Judy Beeler; Ann M Arvin
Journal:  J Infect Dis       Date:  2013-01-08       Impact factor: 5.226

Review 4.  B-cell responses to vaccination at the extremes of age.

Authors:  Claire-Anne Siegrist; Richard Aspinall
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

5.  Early Measles Vaccination During an Outbreak in the Netherlands: Short-Term and Long-Term Decreases in Antibody Responses Among Children Vaccinated Before 12 Months of Age.

Authors:  Iris D Brinkman; Jelle de Wit; Gaby P Smits; Hinke I Ten Hulscher; Maria C Jongerius; Taymara C Abreu; Fiona R M van der Klis; Susan J M Hahné; Marion P G Koopmans; Nynke Y Rots; Debbie van Baarle; Robert S van Binnendijk
Journal:  J Infect Dis       Date:  2019-07-19       Impact factor: 5.226

6.  Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting: study protocol for a randomized controlled trial.

Authors:  Dorthe Maria Vittrup; Anne Cathrine Lund Laursen; Michelle Malon; Jesper Kiehn Soerensen; Jakob Hjort; Soren Buus; Jannet Svensson; Lone Graff Stensballe
Journal:  Trials       Date:  2020-12-10       Impact factor: 2.279

7.  Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis.

Authors:  Laura M Nic Lochlainn; Brechje de Gier; Nicoline van der Maas; Rob van Binnendijk; Peter M Strebel; Tracey Goodman; Hester E de Melker; William J Moss; Susan J M Hahné
Journal:  Lancet Infect Dis       Date:  2019-09-20       Impact factor: 25.071

8.  Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis.

Authors:  Sara Carazo; Marie-Noëlle Billard; Amélie Boutin; Gaston De Serres
Journal:  BMC Infect Dis       Date:  2020-03-29       Impact factor: 3.090

9.  Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis.

Authors:  Laura M Nic Lochlainn; Brechje de Gier; Nicoline van der Maas; Peter M Strebel; Tracey Goodman; Rob S van Binnendijk; Hester E de Melker; Susan J M Hahné
Journal:  Lancet Infect Dis       Date:  2019-09-20       Impact factor: 25.071

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.